Japanese distributor of medical equipment that also plans and builds hospital facilities.
Japanese distributor of medical equipment that also plans and builds hospital facilities.
Earns distribution margins as hospitals order equipment and supplies from it, and hospital construction projects bring larger one-off contracts. Dispensing pharmacies and elder-care services add a steadier line. Many of its hospital relationships are long-standing.
In one line: A medical-equipment distributor plus hospital-facility planner, unlike a single US peer.
Moat: narrow (customer qualification, distribution). Combining equipment sales with facility design/construction locks in long hospital relationships.
Headquarters: Hiroshima, Japan · Founded: 1948 · Employees: 7,819
Size Ship Healthcare (3360.T) is a Japan Health Care company (Medical Distributors) with a market value of $1.38B, the 601st largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,558 on 18 Nov 2026.
Performance Over six months the shares gained 19.3%, against -0.5% for the median peer and -1.4% for the Japan market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 6.5% over the last twelve months (peer median +5.5%); the operating margin is 3.3% (peer median 3.5%).
Valuation It trades at 14.6× forward earnings against a peer median of 16.5× (5th cheapest of 15).
Price implies For today's price to make sense, revenue must grow about -15% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -22 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 13.0 points above its cost of capital (5.0% WACC).
Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥747B | ¥718B | ¥678B | ¥631B | ¥572B |
| Revenue growth | — | +6% | +7% | +10% | — |
| Gross profit | ¥67.8B | ¥66.7B | ¥66.7B | ¥65.6B | ¥60.6B |
| EBITDA | ¥32.1B | ¥31.6B | ¥32.2B | ¥31.9B | ¥28.6B |
| Net income | ¥14.1B | ¥13.4B | ¥15.1B | ¥13.8B | ¥12.1B |
| Free cash flow | n/a | ¥17.8B | ¥16.6B | ¥28.4B | ¥10.6B |
| Capital expenditure | n/a | ¥4.71B | ¥4.18B | ¥3.52B | ¥3.91B |
| Total debt | ¥26.8B | ¥31.9B | ¥39.3B | ¥59.9B | ¥76.0B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Ship Healthcare 3360.T | $1.38B | +19% | +6% | 3% | 14.6× | -14.5% |
| AS ONE 7476.T | $1.10B | +25% | +10% | 12% | 18.4× | 0.0% |
| NIPRO 8086.T | $1.68B | -11% | +5% | 5% | 15.8× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 3360.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.4% | -0.1% | 11th highest of 21 |
| 6-month return | +19.3% | -0.5% | 7th highest of 21 |
| Distance from 52-week high | -9.9% | -18.5% | 5th highest of 21 |
| Revenue growth (TTM) | +6.5% | +5.5% | 9th highest of 21 |
| Operating margin | 3.3% | 3.5% | 11th highest of 21 |
| Forward P/E | 14.6× | 16.5× | 5th cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | -14.5% | -1.3% | least demanding of 17 |
| Growth delivered (Del g) | +7.6% | +6.1% | 8th highest of 17 |
| Hurdle (Req g minus delivered) | -22.2 pp | -7.2 pp | least demanding of 17 |
| ROIC minus cost of capital | +13.0 pp | +0.8 pp | highest of 21 |
| Net debt / EBITDA | -1.7× | 1.5× | 4th least indebted of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ship Healthcare 3360.T | Japan | $1.38B | +19% | +6% | 3% | 14.6× | -14.5% | +7.6% |
| Redcare Pharmacy RDC.DE | Germany | $1.50B | +53% | +19% | 0% | n/a | n/a | n/a |
| Toho 8129.T | Japan | $1.64B | -5% | +4% | 1% | 22.2× | -4.6% | +5.1% |
| Shinva Medical Instrument 600587.SS | China | $1.10B | -10% | +6% | 5% | 13.4× | -6.9% | +1.2% |
| AS ONE 7476.T | Japan | $1.10B | +25% | +10% | 12% | 18.4× | 0.0% | +6.3% |
| DocMorris DOCM.SW | Switzerland | $1.08B | +169% | +11% | -8% | n/a | n/a | n/a |
| Shanghai C and D INNOSTIC Medical Technology 301584.SZ | China | $1.06B | -33% | +8% | 3% | n/a | -2.7% | +17.9% |
| Nanjing Pharmaceutical 600713.SS | China | $999M | -2% | +3% | 2% | n/a | n/a | n/a |
| Guangxi LiuYao 603368.SS | China | $975M | +1% | +2% | 5% | 9.5× | -9.7% | +6.0% |
| Arjo ARJO-B.ST | Sweden | $974M | +42% | 0% | 8% | 21.1× | -1.0% | +3.9% |
| Entero Healthcare Solutions ENTERO.NS | India | $925M | +60% | +35% | 4% | 47.7× | 24.7% | +29.9% |
| Shanghai Haohai Biological Technology 6826.HK | Hong Kong | $897M | -24% | -5% | -2% | 7.7× | 17.0% | +12.4% |
| Suzuken 9987.T | Japan | $2.36B | +8% | +5% | 1% | 15.8× | -10.4% | +3.2% |
| Neuca NEU.WA | Poland | $795M | -9% | +8% | 2% | 15.3× | 5.3% | +8.1% |
| Hanmi Science 008930.KS | South Korea | $2.58B | +48% | +6% | 4% | n/a | 26.0% | +9.6% |
| Asker Healthcare ASKER.ST | Sweden | $2.69B | -14% | +12% | 7% | 24.8× | 4.7% | +12.7% |
| Alfresa 2784.T | Japan | $2.81B | -3% | +4% | 1% | 18.4× | -8.4% | +3.5% |
| COSMOS Pharmaceutical 3349.T | Japan | $3.21B | +2% | +9% | 4% | 15.9× | n/a | n/a |
| Arata 2733.T | Japan | $576M | -3% | +3% | 1% | 12.0× | -6.2% | +3.8% |
| Shanghai New World 600628.SS | China | $573M | -10% | -2% | 6% | n/a | -1.6% | +1.0% |
| Amplifon AMP.MI | Italy | $3.39B | +8% | 0% | 10% | 17.0× | 6.8% | +9.8% |